EUVIMEDEUVIMED entdecken
Crossref

Systemic Treatment Strategies and Outcomes of Patients With Synchronous Peritoneal Metastases of Gastric Origin: A Nationwide Population-Based Study

Niels A D Guchelaar, Bo J Noordman, Marion W Welten, Myron T van Santen, Micha J de Neijs, Stijn L W Koolen, Rob H A Verhoeven, Esther Oomen-de Hoop, Pieter C van der Sluis, Sjoerd M Lagarde, Hanneke W M van Laarhoven, Ignace H J T de Hingh und 4 weitere

Journal of the National Comprehensive Cancer Network · 2024

DOI: 10.6004/jnccn.2024.7013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2024. Verfasst von Niels A D Guchelaar und 15 weiteren Autor:innen. Beteiligte Einrichtung: 1Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Peritoneal Neoplasms, Stomach Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Palliative systemic treatment is currently standard of care for metastatic gastric cancer. However, patients with peritoneal metastases of gastric origin are often underrepresented in clinical studies due to unmeasurable radiologic disease. This study describes the systemic treatment strategies and outcomes in patients with peritoneal metastases in a nationwide real-world setting.

Methods

Patients with gastric adenocarcinoma and synchronous peritoneal metastases (with or without other metastases) diagnosed in the Netherlands between 2015 and 2020 were identified from the nationwide Netherlands Cancer Registry. Median overall survival (OS) and time-to-treatment failure were determined and multivariable Cox regression analyses were used to compare treatment groups, corrected for relevant tumor and patient characteristics.

Results

In total, 1,972 patients were included, of whom 842 (43%) were treated with palliative systemic therapy. The majority received capecitabine + oxaliplatin (CAPOX; 44%), followed by fluorouracil/leucovorin/oxaliplatin (FOLFOX; 19%), and epirubicin + capecitabine + oxaliplatin (EOX; 8%). Of the 99 (45%) patients who received second-line systemic treatment, ramucirumab + paclitaxel were administered most frequently (63%). After adjustment for sex, age, comorbidities, performance status, tumor location, Lauren classification, and the presence of metastases outside of the peritoneum, patients treated with a triplet containing docetaxel and those treated with a regimen containing trastuzumab had a significantly longer OS compared with patients treated with a doublet containing a fluoropyrimidine derivate + oxaliplatin (hazard ratio [HR], 0.69; 95% CI, 0.52–0.91, and HR, 0.68; 95% CI, 0.51–0.91, respectively). Monotherapy was associated with a shorter OS (HR, 2.08, 95% CI, 1.53–2.83).

Conclusions

There is substantial heterogeneity in systemic treatment choices in patients with gastric cancer and peritoneal metastases in the Netherlands. In this study, patients treated with triplets containing docetaxel and with trastuzumab-containing regimens survived longer than patients who received doublet therapy. Despite this, median OS for all treatment groups remained below one year.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peritoneal NeoplasmsStomach NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleMiddle AgedAgedNetherlandsTreatment OutcomeAdenocarcinomaAdultRegistries

Autor:innen und Institutionen

  • 1Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • 2Division of Surgical Oncology and Gastrointestinal Surgery, Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • 3Department of Medical Oncology, Catharina Cancer Institute, Eindhoven, the Netherlands.
  • 4Department of Pharmacy, Erasmus Medical Center, Rotterdam, the Netherlands.
  • 5Department of Research & Development, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, the Netherlands.
  • 6Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands.

Zitieren

APA

Guchelaar, N. A. D., Noordman, B. J., Welten, M. W., van Santen, M. T., de Neijs, M. J., Koolen, S. L. W., Verhoeven, R. H. A., Oomen-de Hoop, E., van der Sluis, P. C., Lagarde, S. M., van Laarhoven, H. W. M., de Hingh, I. H. J. T., Creemers, G. J., Mostert, B., Wijnhoven, B. P. L., & Mathijssen, R. H. J. (2024). Systemic Treatment Strategies and Outcomes of Patients With Synchronous Peritoneal Metastases of Gastric Origin: A Nationwide Population-Based Study. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2024.7013

Vancouver

Guchelaar NAD, Noordman BJ, Welten MW, van Santen MT, de Neijs MJ, Koolen SLW, et al. Systemic Treatment Strategies and Outcomes of Patients With Synchronous Peritoneal Metastases of Gastric Origin: A Nationwide Population-Based Study. Journal of the National Comprehensive Cancer Network. 2024. doi:10.6004/jnccn.2024.7013

BibTeX
@article{Guchelaar2024,
  author = {Guchelaar, Niels A D and Noordman, Bo J and Welten, Marion W and van Santen, Myron T and de Neijs, Micha J and Koolen, Stijn L W and Verhoeven, Rob H A and Oomen-de Hoop, Esther and van der Sluis, Pieter C and Lagarde, Sjoerd M and van Laarhoven, Hanneke W M and de Hingh, Ignace H J T and Creemers, Geert-Jan and Mostert, Bianca and Wijnhoven, Bas P L and Mathijssen, Ron H J},
  title = {Systemic Treatment Strategies and Outcomes of Patients With Synchronous Peritoneal Metastases of Gastric Origin: A Nationwide Population-Based Study},
  journal = {Journal of the National Comprehensive Cancer Network},
  year = {2024},
  doi = {10.6004/jnccn.2024.7013}
}
Kostenlos starten →